Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CULLINAN ONCOLOGY, INC.

(CGEM)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
11.77 USD   -1.18%
02/02Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
GL
02/02Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
GL
02/01Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société CULLINAN ONCOLOGY, INC.
02/02Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and t..
GL
02/02Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and t..
GL
02/01Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
01/24Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application ..
GL
01/24Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application ..
AQ
01/19Cullinan Oncology, Inc. : Unregistered Sale of Equity Securities, Amendments to Articles o..
AQ
01/06Cullinan Oncology : Corporate Presentation January 2023
PU
01/03Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Cullinan Oncology : Corporate Presentation December 2022
PU
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
2022CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
2022Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Re..
GL
2022Cullinan Oncology, Inc. : Change in Directors or Principal Officers, Financial Statements ..
AQ
2022Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Dire..
GL
2022Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Dire..
AQ
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Cullinan Oncology to Participate in Upcoming Investor Conferences
GL
2022Cullinan Oncology, Inc. : Entry into a Material Definitive Agreement, Regulation FD Disclo..
AQ
2022Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which ..
GL
2022Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which ..
AQ
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
2022Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and ..
GL
2022Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and ..
AQ
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer
GL
2022Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer
GL
2022Cullinan Oncology : Provides Corporate Update and Reports Second Quarter 2022 Financial Re..
PU
2022CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
2022Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial R..
GL
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
2022Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth ..
GL
2022Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth ..
AQ
2022Cullinan Oncology to Participate in William Blair Biotech Focus Conference
GL
2022Cullinan Oncology to Participate in William Blair Biotech Focus Conference
AQ
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Cullinan Oncology : UNAUDITED PRO FORMA FINANCIAL INFORMATION - Form 8-K
PU
2022Cullinan Oncology, Inc. : Completion of Acquisition or Disposition of Assets, Regulation F..
AQ
2022Cullinan Oncology, Inc. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2022Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaborati..
GL
2022Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaborati..
GL
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CL..
GL
2022Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CL..
AQ
2022Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting
GL
2022Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
GL
2022Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
AQ
2022CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
2022Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Re..
GL
2022Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Re..
AQ
2022Cullinan Oncology, Inc. : Entry into a Material Definitive Agreement, Results of Operation..
AQ
2022Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly ..
GL
2022Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly ..
AQ
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN..
AQ
2022Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences
AQ
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Ex..
AQ
2022CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
2022Cullinan Oncology : Provides Corporate Update and Reports Fourth Quarter and Full Year 202..
PU
2022Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 20..
GL
2022Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 20..
GL
2022Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022
AQ
2022Cullinan Oncology to Present at the Barclays Global Healthcare Conference
AQ
2022Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Onco..
GL
2022Cullinan Oncology, Inc. : Change in Directors or Principal Officers, Financial Statements ..
AQ
2022Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of J..
AQ
2022Cullinan Oncology to Present at SVB Leerink's 11th Annual Global Healthcare Conference
AQ
2022Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance O..
GL
2022Cullinan Oncology to Present at Upcoming Virtual Investor Conferences
AQ
1  2Next